Clinical Trials
- Digestive System
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
- Ages18 years - 75 years
- GenderBoth
- Digestive System
Efficacy & Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis
- Ages16 years - 80 years
- GenderBoth
- Digestive System
Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
- Ages18 years and older
- GenderBoth
- Digestive System
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Ages12 years - 75 years
- GenderBoth
- Digestive System
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- Ages18 years - 80 years
- GenderBoth
- Digestive System
test
- Ages18 years - 75 years
- GenderBoth